12 Feb TUMAGNOSTIC – Phase 1 clinical trial
Convert Pharmaceuticals, a Belgian biotech company developing anti-cancer therapeutics, has obtained very promising pre-clinical results with CP-506 drug, a new and improved Hypoxia Activated Prodrug. The company is finalising its Clinical Trial Application to obtain regulatory approval for the launch of its tumor agnostic Phase I Clinical Trial in 2021. This will be a first in human dose escalation study to determine the safety, pharmacokinetics, pharmacodynamics and phase 2 recommended dose. At the same time, we will check for the first indication of antitumor effect in humans.
CP-506 will be tested in both monotherapy, with patient selection based on validated biomarkers, as well as in combination with standard treatments such as immune checkpoint inhibitors.
We expect that by 2024 we will have completed the study with results that prompt us to continue the clinical development of CP-506 as the first antitumor drug from the HAP class.